Healthcare solutions provider Solventum (NYSE: SOLV) reported Q3 2026 results topping the market’s revenue expectations, but sales fell by 7% year on year to $1.95 billion. Its non-GAAP profit of $1.45 per share was 7.9% above analysts’ consensus estimates.

Is now the time to buy SOLV? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Solventum’s latest quarter reflected effective execution amid significant operational changes, with the market responding positively to the company’s performance. Management cited the successful completion of the largest ERP cutover in Solventum’s history as a key factor, noting that this milestone supported continued product delivery and minimized disruption for customers. CEO Bryan Hanson emphasized that cross-functional teamwork enabled the company to navigate this complex transition, stating, “This team delivered through it… and that kind of team dynamic under that kind of pressure isn’t something you can just install.” The quarter’s results were also influenced by the reversal of advanced orders put in place ahead of the ERP cutover, which impacted reported sales but was anticipated by management. Portfolio optimization and new product launches in areas like wound therapy and dental solutions were additional contributors to performance.

Looking ahead, Solventum’s raised profit guidance is anchored in ongoing transformation initiatives, the near-completion of its separation from 3M, and a sharpened focus on high-potential segments. Management expects margin expansion to be driven by benefits from a new long-term supply agreement with 3M, ongoing cost savings programs, and the continued ramp of recently launched products. CFO Wayde McMillan expressed confidence in the company’s ability to expand margins next year, despite the headwind from one-time tariff refunds, highlighting, “We do have a lot of confidence in margin expansion for next year.” The planned separation of the Health Information Systems business and integration of recent acquisitions are expected to provide further opportunities for strategic focus and operational improvement.

Key insights from management’s remarks

Management attributed the quarter’s performance to the ERP system transition, ongoing portfolio optimization, and the ramp-up of key growth drivers, while highlighting the impact of advanced order reversals and new product contributions.

• ERP system transition impact: The company completed its largest ERP cutover to date, which was necessary for the ongoing separation from 3M. While the transition was complex, mitigation plans held, and product supply to customers continued largely uninterrupted.
• Separation progress and cost roll-off: With over 90% of the separation from 3M now complete, management expects a reduction in separation-related costs to improve free cash flow significantly in upcoming quarters. This is a major milestone that reduces execution risk for the business.
• Portfolio optimization initiatives: Solventum advanced its portfolio optimization strategy, including plans to separate the Health Information Systems (HIS) business. The company is evaluating both spin and sale options, aiming for enhanced strategic clarity and focused investment for both the remaining and separated entities.
• Growth driver execution: The company’s five growth driver areas—negative pressure wound therapy, IV site management, sterilization assurance, core restoratives, and revenue cycle management—were highlighted as central to organic growth. Management pointed to the under-penetration of existing therapies, such as the V.A.C. System, as a significant opportunity for future expansion.
• New product traction and regulatory milestones: The launch of the V.A.C. Peel and Place dressing and the 510(k) clearance for combined use of Restrata with V.A.C. Therapy were cited as important product advances. These innovations are designed to simplify workflows and improve patient experience, supporting adoption and market share gains.

Drivers of future performance

Management expects continued margin expansion and revenue growth, driven by operational improvements, new product ramp-up, and strategic portfolio moves.

• Margin expansion focus: Management’s outlook is shaped by ongoing cost-saving programs, the renegotiated supply agreement with 3M, and the anticipated reduction in separation-related expenses. These factors are expected to support margin improvement even as one-time tariff benefits roll off.
• Strategic portfolio actions: The planned separation of the Health Information Systems business is expected to streamline the company’s structure and sharpen its focus on core areas, though management acknowledges a near-term margin dilution of approximately 400 basis points. Proceeds from the separation are expected to be used for debt reduction and potential shareholder returns.
• Organic growth through product penetration: The company’s growth strategy centers on increasing penetration of clinically differentiated products in existing accounts, leveraging recently launched innovations, and integrating acquisitions like Acera. Management sees significant opportunity in markets where current therapies are underutilized, particularly in wound care and dental solutions.

Catalysts in upcoming quarters

In the quarters ahead, the StockStory team will be monitoring (1) execution on the final stages of the 3M separation and associated cost reductions, (2) progress on the planned Health Information Systems business separation, including clarity on the method and financial impact, and (3) further traction of new product launches in wound therapy and dental. We will also watch for updates on integration of recent acquisitions and the sustainability of margin improvements.

Solventum currently trades at $87.74, in line with $87.18 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks that trumped tariffs

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.